Suppression of Recurrent Transient Ischemic Attacks by a Statin Agent
Neurol 56:531-532, Alberts,M.J., 2001
Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001
Encephalitis Associated with Glutamic Acid Decarboxylase Autoantibodies
Neurol 56:814, Marchiori,G.C.,et al, 2001
Onset of Multiple Sclerosis Associated With Anti-TNF Therapy
Neurol 57:1885-1888, Sicotte,N.L. &Voskuhl,R.R., 2001
Adverse Effects of Antiretroviral Therapy
Lancet 356:1423-1430, Carr,A. &Cooper, D.A., 2000
A 5-Month, Randomized, Placebo-controlled Trial of Galantamine in AD
Neurol 54:2269-2276, Tariot,P.N.,et al, 2000
Galantamine in AD
Neurol 54:2261-2268, Raskind,M.A.,et al, 2000
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Cholesterol and Strokes
BMJ 320:459-460, Oliver,M.F., 2000
HMG-CoA Reductase Inhibitors (Statins)
Neurol 54:790-795, Hess,D.C.,et al, 2000
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Depression in Parkinson's Disease
BMJ 320:1287-1288, Allain,H.,et al, 2000
Axial Parkinsonian Symptoms Can Be Improved: The Role of Levodopa and Bilateral Subthalamic Stimulation
JNNP 68:595-600, Bejjani,B.P.,et al, 2000
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Pyridostigmine-Induced Microcephaly
Neurol 54:1873-1874, Niesen,C.E.&Shah,N.S., 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Prevention of Radiographic-Contrast-Agent-Induced Reductions In Renal Function by Acetylcysteine
NEJM 343:180-184,210, Tepel,J. et al, 2000
Pravastatin Therapy and The Risk of Stroke
NEJM 343:317-326, White,H.D. et al, 2000
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Incidence and Prevalence of Neurological Disorders Associated with HIV Since the Introduction of Highly Active Antiretroviral Therapy (HAART)
JNNP 69:376-380, Maschke,M. et al, 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Antioxidant Therapy in Neurologic Disease
Arch Neurol 57:1265-1270, Delanty,N. & Dichter,M.A., 2000
Vitamin E and Beta Carotene Supplementation in High Risk for Stroke
Arch Neurol 57:1503-1509, Leppala,J.M.,et al, 2000
Statins and the Risk of Dementia
Lancet 356:1627-1631, Jick,H.,et al, 2000
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease
JAMA 284:1931-1938,1971, Parkinson Study Group, 2000
AIDS-Related Focal Brain Lesions in the Era of Highly Active Antiretroviral Therapy
Neurol 55:1194-1200, Ammassari,A.,et al, 2000
Intake of Flavonoids, Carotenoids,Vitamins C and E, and Risk of Stroke in Male Smokers
Stroke 31:2301-2306, Hirvonen,T.,et al, 2000
Acetazolamide Treatment for Migraine Aura Status
Neurol 55:1588-1589, Haan,J.,et al, 2000
The Clinical Spectrum of Anti-GAD Antibody-Positive Patients with Stiff-Person Syndrome
Neurol 55:1531-1535, Dalakas,M.C.,et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
An Overview of Acute Stroke Therapy
Arch Int Med 160:3196-3206, Fisher,M. & Schaebitz,W., 2000
Prevention of Ischaemic Stroke
BMJ 321:1455-1459, Gubitz,G. & Sandercock,P., 2000
Efficacy of Rivastigmine in Dementia with Lewy Bodies: a Randomised, Double-blind, Placebo-controlled International Study
Lancet, 356:2031-2036,2024, McKeith,I.,et al, 2000
Selegiiline and Mortality in Subjects with Parkinson's Disease
Neurol 55:1785-1789,1770, Donnan,P.T.,et al, 2000
A Controlled Study of Additional sr-L-dopa in L-dopa-responsive Restless Legs Syndrome with Late-Night Symptoms
Neurol 52:285-290, Collado-Seidel,V.,et al, 1999
HAART Improves Prognosis in HIV-Associated Progressive Multifocal Leukoencephalopathy
Neurol 52:623-625,440, Clifford,D.B.,et al, 1999
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Diagnostic Criteria for Parkinson Disease
Arch Neurol 56:33-39, Gelb,D.J.,et al, 1999
Relation of Consumption of Vitamin E, Vitamin C, and Carotenoids to Risk for Stroke among Men in the United States
Ann Int Med 130:963-970, Ascherio,A.,et al, 1999
Randomized Trial of Sildenafil for the Treatment of Erectile Dysfunction in Spinal Cord Injury
Ann Neurol 46:15-21, Giuliano,F.,et al, 1999
Rapid-Onset Dystonia-Parkinsonism:Linkage to Chromosome 19q13
Ann Neurol 46:176-182, Kramer,P.L.,et al, 1999
Effect of Aldose Reductase Inhibition on Nerve Conduction and Morphomedtry in Diabetic Neuropathy
Neurol 53:580-591, Greene,D.A.,et al, 1999
Neuroprotective Properties of Statins in Cerebral Ischemia and Stroke
Stroke 30:1969-1973, Vaughan,C.J.&Delanty,N., 1999
Immediate-Release and Controlled-Release Carbidopa/Levodopa in PD, A 5-Year Randomized Multicenter Study
Neurol 53:1012-1019, Koller,W.C.,et al, 1999
Clinical Benefits of Donepezil:Results from a Long-Term Phase III Extension Trial
Neurol 52:A174, Doody,R.S.,et al, 1999
Neostigmine for the Treatment of Acute Colonic Pseudo-Obstruction
NEJM 341:137-141, Ponec,R.J.,et al, 1999
Is Cholesterol a Risk Factor for Stroke? No
Arch Neurol 56:1521-1524, Landau,W.M., 1999
Is Cholesterol a Risk Factor for Stroke? Yes
Arch Neurol 56:1518-1520,1524, Demchuk,A.M.,et al, 1999